DK0968208T3 - Quinolin- og quinazolin-forbindelser som er nyttige i terapi især til behandling af godartet prostatisk hyperplasia - Google Patents

Quinolin- og quinazolin-forbindelser som er nyttige i terapi især til behandling af godartet prostatisk hyperplasia

Info

Publication number: DK0968208T3
Authority: DK; Denmark
Prior art keywords: quinoline; treatment; compounds useful; benign prostatic; prostatic hyperplasia
Prior art date: 1997-01-11

Application number

DK98904058T

Other languages

Danish (da)

English (en)

Inventor

David Nathan Abraham Pfize Fox

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-01-11

Filing date

1998-01-06

Publication date

2003-07-28

1998-01-06 Application filed by Pfizer filed Critical Pfizer

2003-07-28 Application granted granted Critical

2003-07-28 Publication of DK0968208T3 publication Critical patent/DK0968208T3/da

Links

SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 2
206010004446 Benign prostatic hyperplasia Diseases 0.000 title 1
208000004403 Prostatic Hyperplasia Diseases 0.000 title 1
125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title 1
238000002560 therapeutic procedure Methods 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

DK98904058T 1997-01-11 1998-01-06 Quinolin- og quinazolin-forbindelser som er nyttige i terapi især til behandling af godartet prostatisk hyperplasia DK0968208T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9700504.5A GB9700504D0 (en)	1997-01-11	1997-01-11	Pharmaceutical compounds
PCT/EP1998/000143 WO1998030560A1 (en)	1997-01-11	1998-01-06	Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of begnin prostatic hyperplasia

Publications (1)

Publication Number	Publication Date
DK0968208T3 true DK0968208T3 (da)	2003-07-28

Family

ID=10805838

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK98904058T DK0968208T3 (da)	1997-01-11	1998-01-06	Quinolin- og quinazolin-forbindelser som er nyttige i terapi især til behandling af godartet prostatisk hyperplasia

Country Status (45)

Country	Link
US (4)	US6169093B1 (id)
EP (1)	EP0968208B1 (id)
JP (1)	JP3357677B2 (id)
KR (1)	KR100347472B1 (id)
CN (2)	CN1093858C (id)
AP (1)	AP819A (id)
AR (1)	AR010396A1 (id)
AT (1)	ATE242238T1 (id)
AU (1)	AU724990B2 (id)
BG (1)	BG63918B1 (id)
BR (1)	BR9807068A (id)
CA (1)	CA2277473C (id)
CZ (1)	CZ295580B6 (id)
DE (1)	DE69815313T2 (id)
DK (1)	DK0968208T3 (id)
DZ (1)	DZ2394A1 (id)
EA (1)	EA002851B1 (id)
ES (1)	ES2198695T3 (id)
GB (1)	GB9700504D0 (id)
HK (1)	HK1054389B (id)
HN (1)	HN1998000002A (id)
HR (1)	HRP980010B1 (id)
HU (1)	HUP0000942A3 (id)
ID (1)	ID21863A (id)
IL (1)	IL130762A (id)
IS (1)	IS2012B (id)
MA (1)	MA26465A1 (id)
MY (1)	MY119623A (id)
NO (1)	NO318609B1 (id)
NZ (1)	NZ336302A (id)
OA (1)	OA11074A (id)
PA (1)	PA8444301A1 (id)
PE (1)	PE44499A1 (id)
PL (1)	PL334678A1 (id)
PT (1)	PT968208E (id)
SA (1)	SA97180705B1 (id)
SI (1)	SI0968208T1 (id)
SK (1)	SK284779B6 (id)
TN (1)	TNSN98004A1 (id)
TR (1)	TR199901604T2 (id)
TW (1)	TW444013B (id)
UA (1)	UA62945C2 (id)
WO (1)	WO1998030560A1 (id)
YU (1)	YU31699A (id)
ZA (1)	ZA98166B (id)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9700504D0 (en)	1997-01-11	1997-02-26	Pfizer Ltd	Pharmaceutical compounds
GB9708917D0 (en) *	1997-05-01	1997-06-25	Pfizer Ltd	Compounds useful in therapy
IL141235A (en)	2000-02-09	2012-04-30	Novartis Int Pharm Ltd	Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
AU779118B2 (en) *	2000-03-03	2005-01-06	Pfizer Inc.	4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3, 4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylate and polymorphs
BR0113585A (pt)	2000-08-31	2003-07-29	Hoffmann La Roche	Derivados quinazolina como antagonistas adrenérgicos alfa-1
US6900220B2 (en)	2001-01-02	2005-05-31	Syntex (U.S.A.) Llc	Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
CA2432578C (en) *	2001-01-02	2008-04-01	F. Hoffmann-La Roche Ag	Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists
US6734303B2 (en)	2001-05-18	2004-05-11	Pfizer Inc.	Process for the production of quinazolines
GB0112061D0 (en) *	2001-05-18	2001-07-11	Pfizer Ltd	Process for the production of quinazolines
GB0118752D0 (en) *	2001-08-01	2001-09-26	Pfizer Ltd	Process for the production of quinazolines
GB0124455D0 (en) *	2001-10-11	2001-12-05	Pfizer Ltd	Pharmaceutical formulations
US7163696B2 (en)	2001-10-11	2007-01-16	Pfizer Inc.	Pharmaceutical formulations
GB0206033D0 (en)	2002-03-14	2002-04-24	Pfizer Ltd	Compounds useful in therapy
EP2280003B1 (en)	2002-07-15	2014-04-02	Symphony Evolution, Inc.	Process for preparing receptor-type kinase modulators
GB0219961D0 (en)	2002-08-28	2002-10-02	Pfizer Ltd	Oxytocin inhibitors
GB0221579D0 (en) *	2002-09-17	2002-10-23	Pfizer Ltd	Combinations of atorvastatin and, adrenergic receptor antagonists
GB0221582D0 (en) *	2002-09-17	2002-10-23	Pfizer Ltd	Method of treatment
BR0314759A (pt)	2002-09-26	2005-07-26	Pfizer	Derivados de pirazol
GB0225908D0 (en) *	2002-11-06	2002-12-11	Pfizer Ltd	Treatment of female sexual dysfunction
WO2004054560A1 (en)	2002-12-13	2004-07-01	Warner-Lambert Company Llc	Alpha-2-delta ligand to treat lower urinary tract symptoms
JP2009513504A (ja) *	2003-07-02	2009-04-02	エフ．ホフマン−ラロシュアーゲー	５−置換キナゾリノン誘導体
US7291640B2 (en)	2003-09-22	2007-11-06	Pfizer Inc.	Substituted triazole derivatives as oxytocin antagonists
PT2213661E (pt)	2003-09-26	2011-12-15	Exelixis Inc	Moduladores de c-met e métodos de uso
WO2005089804A2 (en) *	2004-03-16	2005-09-29	Pfizer Limited	Combinations of hmg-coa reductase inhibitors and alpha1 adrenergic receptor antagonists
KR20050092519A (ko) *	2004-03-16	2005-09-22	화이자 인코포레이티드	아토르바스타틴 및 α1-아드레날린성 수용체 길항제의 조합
BRPI0510453A (pt)	2004-04-30	2007-10-30	Warner Lambert Co	composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
WO2008084493A2 (en) *	2007-01-09	2008-07-17	Unichem Laboratories Limited	A novel process for the preparation of 2-halo-4-aminoquinazolines
JP2009126785A (ja) *	2007-11-19	2009-06-11	Mitsubishi Gas Chem Co Inc	２−ヨード−３，４−ジメトキシベンゾニトリルの製造方法
JP2009126784A (ja) *	2007-11-19	2009-06-11	Mitsubishi Gas Chem Co Inc	２−ヨード−３，４−ジメトキシベンゾニトリルの製造方法。
SG173014A1 (en)	2009-01-16	2011-08-29	Exelixis Inc	Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US9938292B2 (en)	2014-03-24	2018-04-10	Guangdong Zhongsheng Pharmaceutical Co., Ltd	Quinoline derivatives as SMO inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US875506A (en) *	1907-03-19	1907-12-31	Berry H Collins	Guiding attachment for penholders.
GB1390014A (en) *	1971-05-07	1975-04-09	Koninklijke Pharma Fab Nv	Process for the preparation of carbocyclic fused pyrimidine derivatives
US4026894A (en) *	1975-10-14	1977-05-31	Abbott Laboratories	Antihypertensive agents
US4098788A (en) *	1977-06-20	1978-07-04	Bristol-Myers Company	Process for preparing quinazolines
US4656174A (en)	1982-07-24	1987-04-07	Pfizer Inc.	Quinoline therapeutic agents
GB8506174D0 (en) *	1985-03-09	1985-04-11	Pfizer Ltd	4-amino-6 7-dimethoxy-2-piperazin-1-ylquinazoline derivatives
IT1270993B (it)	1994-03-18	1997-05-26	Recordati Chem Pharm	Derivati chinzolilamminici attivi come alfa-antagonisti
NZ325248A (en)	1995-12-23	1999-09-29	Pfizer Res & Dev	Quinoline and quinazoline compounds useful in therapy
GB9700504D0 (en)	1997-01-11	1997-02-26	Pfizer Ltd	Pharmaceutical compounds
GB9708917D0 (en) *	1997-05-01	1997-06-25	Pfizer Ltd	Compounds useful in therapy
GB9711650D0 (en)	1997-06-05	1997-07-30	Pfizer Ltd	Compounds useful in therapy

1997
- 1997-01-11 GB GBGB9700504.5A patent/GB9700504D0/en active Pending
- 1997-11-18 TW TW086117203A patent/TW444013B/zh not_active IP Right Cessation
- 1997-12-13 SA SA97180705A patent/SA97180705B1/ar unknown
1998
- 1998-01-05 PE PE1998000006A patent/PE44499A1/es not_active Application Discontinuation
- 1998-01-05 HN HN1998000002A patent/HN1998000002A/es unknown
- 1998-01-06 NZ NZ336302A patent/NZ336302A/xx unknown
- 1998-01-06 SK SK907-99A patent/SK284779B6/sk unknown
- 1998-01-06 CN CN98801748A patent/CN1093858C/zh not_active Expired - Fee Related
- 1998-01-06 KR KR1019997006241A patent/KR100347472B1/ko not_active Expired - Fee Related
- 1998-01-06 AT AT98904058T patent/ATE242238T1/de not_active IP Right Cessation
- 1998-01-06 WO PCT/EP1998/000143 patent/WO1998030560A1/en not_active Ceased
- 1998-01-06 PL PL98334678A patent/PL334678A1/xx unknown
- 1998-01-06 US US09/341,228 patent/US6169093B1/en not_active Expired - Lifetime
- 1998-01-06 EP EP98904058A patent/EP0968208B1/en not_active Expired - Lifetime
- 1998-01-06 AP APAP/P/1998/001175A patent/AP819A/en active
- 1998-01-06 CZ CZ19992436A patent/CZ295580B6/cs not_active IP Right Cessation
- 1998-01-06 CA CA002277473A patent/CA2277473C/en not_active Expired - Fee Related
- 1998-01-06 TR TR1999/01604T patent/TR199901604T2/xx unknown
- 1998-01-06 YU YU31699A patent/YU31699A/sh unknown
- 1998-01-06 ES ES98904058T patent/ES2198695T3/es not_active Expired - Lifetime
- 1998-01-06 IL IL13076298A patent/IL130762A/xx not_active IP Right Cessation
- 1998-01-06 ID IDW990660A patent/ID21863A/id unknown
- 1998-01-06 JP JP53056598A patent/JP3357677B2/ja not_active Expired - Lifetime
- 1998-01-06 PT PT98904058T patent/PT968208E/pt unknown
- 1998-01-06 SI SI9830477T patent/SI0968208T1/xx unknown
- 1998-01-06 BR BR9807068-1A patent/BR9807068A/pt not_active Application Discontinuation
- 1998-01-06 DK DK98904058T patent/DK0968208T3/da active
- 1998-01-06 CN CNB011432918A patent/CN1191249C/zh not_active Expired - Fee Related
- 1998-01-06 DE DE69815313T patent/DE69815313T2/de not_active Expired - Lifetime
- 1998-01-06 PA PA19988444301A patent/PA8444301A1/es unknown
- 1998-01-06 AU AU62088/98A patent/AU724990B2/en not_active Ceased
- 1998-01-06 EA EA199900531A patent/EA002851B1/ru not_active IP Right Cessation
- 1998-01-06 HU HU0000942A patent/HUP0000942A3/hu unknown
- 1998-01-07 TN TNTNSN98004A patent/TNSN98004A1/fr unknown
- 1998-01-07 MA MA24920A patent/MA26465A1/fr unknown
- 1998-01-08 HR HR980010A patent/HRP980010B1/xx not_active IP Right Cessation
- 1998-01-08 AR ARP980100091A patent/AR010396A1/es unknown
- 1998-01-09 ZA ZA98166A patent/ZA98166B/xx unknown
- 1998-01-09 MY MYPI98000094A patent/MY119623A/en unknown
- 1998-06-01 UA UA99073901A patent/UA62945C2/uk unknown
- 1998-06-07 DZ DZ980004A patent/DZ2394A1/xx active
1999
- 1999-06-25 IS IS5093A patent/IS2012B/is unknown
- 1999-07-07 BG BG103560A patent/BG63918B1/bg unknown
- 1999-07-08 OA OA9900152A patent/OA11074A/en unknown
- 1999-07-09 NO NO19993396A patent/NO318609B1/no unknown
2000
- 2000-06-02 US US09/586,503 patent/US6365599B1/en not_active Expired - Fee Related
2001
- 2001-11-13 US US10/007,753 patent/US6521629B2/en not_active Expired - Fee Related
2002
- 2002-12-13 US US10/318,902 patent/US6653302B2/en not_active Expired - Fee Related
2003
- 2003-09-17 HK HK03106677.4A patent/HK1054389B/zh not_active IP Right Cessation

Also Published As

Publication number	Publication date
CA2277473A1 (en)	1998-07-16
CZ9902436A3 (cs)	2000-10-11
TW444013B (en)	2001-07-01
IS2012B (is)	2005-05-13
EP0968208B1 (en)	2003-06-04
ZA98166B (en)	1999-07-09
OA11074A (en)	2002-03-13
US6521629B2 (en)	2003-02-18
MY119623A (en)	2005-06-30
NO993396L (no)	1999-07-09
HN1998000002A (es)	1999-01-08
SK284779B6 (sk)	2005-11-03
IS5093A (is)	1999-06-25
CN1243513A (zh)	2000-02-02
GB9700504D0 (en)	1997-02-26
US20030130259A1 (en)	2003-07-10
US6653302B2 (en)	2003-11-25
YU31699A (sh)	2001-07-10
JP2000507966A (ja)	2000-06-27
ATE242238T1 (de)	2003-06-15
ID21863A (id)	1999-08-05
AP9801175A0 (en)	1998-01-31
TNSN98004A1 (fr)	2005-03-15
US6169093B1 (en)	2001-01-02
PL334678A1 (en)	2000-03-13
NO318609B1 (no)	2005-04-18
PE44499A1 (es)	1999-05-06
PA8444301A1 (es)	2000-05-24
IL130762A (en)	2005-12-18
SA97180705B1 (ar)	2005-12-26
HUP0000942A3 (en)	2002-06-28
EA199900531A1 (ru)	2000-02-28
ES2198695T3 (es)	2004-02-01
MA26465A1 (fr)	2004-12-20
WO1998030560A1 (en)	1998-07-16
HUP0000942A2 (hu)	2001-04-28
IL130762A0 (en)	2001-01-28
EA002851B1 (ru)	2002-10-31
AP819A (en)	2000-04-03
US6365599B1 (en)	2002-04-02
AU724990B2 (en)	2000-10-05
KR100347472B1 (ko)	2002-08-07
BG63918B1 (bg)	2003-06-30
HK1054389B (zh)	2005-10-14
EP0968208A1 (en)	2000-01-05
CN1093858C (zh)	2002-11-06
HK1025327A1 (en)	2000-11-10
DE69815313D1 (de)	2003-07-10
CN1191249C (zh)	2005-03-02
US20020040028A1 (en)	2002-04-04
HRP980010A2 (en)	1998-10-31
TR199901604T2 (xx)	1999-12-21
PT968208E (pt)	2003-09-30
NZ336302A (en)	2000-08-25
DZ2394A1 (fr)	2003-06-04
AU6208898A (en)	1998-08-03
CN1403453A (zh)	2003-03-19
BG103560A (en)	2000-06-30
SK90799A3 (en)	2001-03-12
CZ295580B6 (cs)	2005-08-17
BR9807068A (pt)	2000-05-02
NO993396D0 (no)	1999-07-09
AR010396A1 (es)	2000-06-07
DE69815313T2 (de)	2003-12-11
UA62945C2 (en)	2004-01-15
JP3357677B2 (ja)	2002-12-16
KR20000070022A (ko)	2000-11-25
HRP980010B1 (en)	2002-06-30
SI0968208T1 (en)	2003-10-31
HK1054389A1 (en)	2003-11-28
CA2277473C (en)	2003-08-12

Publication	Publication Date	Title
DK0968208T3 (da)	2003-07-28	Quinolin- og quinazolin-forbindelser som er nyttige i terapi især til behandling af godartet prostatisk hyperplasia
DE60023982D1 (de)	2005-12-22	System zur Behandlung von benigner Prostatahyperplasie
NO976078D0 (no)	1997-12-23	Fremgangsmåte for å behandle godartet prostatisk hyperplasi med varmeterapi
FI931765A7 (fi)	1993-10-21	Steroidijohdannaisia eturauhasen liikakasvun käsittelyyn, niiden valmistus ja käytöt
DK0925069T3 (da)	2007-10-29	Anvendelse af Cetrorelix til behandling af godartet prostatahypertrofi og prostatacancer
AU3011299A (en)	1999-10-18	Combination therapy for the treatment of benign prostatic hyperplasia
AU1316000A (en)	2000-05-15	Compositions and methods for treating benign prostatic hyperplasia using tocotrienols
AU1657097A (en)	1997-10-02	Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
NO995518D0 (no)	1999-11-11	Arylsubstituerte piperaziner brukbare ved behandling av benign prostatisk hyperplasi
DK1054868T3 (da)	2003-12-22	Substituerede pyridinoarylpiperaziner egnede til behandling af prostatahyperplasi
ZA982819B (en)	1999-10-04	Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators.
AU9128998A (en)	1999-03-22	Composition and method for the treatment of benign prostatic hyperplasia and prostatitis
BR9608912A (pt)	1999-03-02	Agonistas de meletonina para o tratamento de hiperplasia prostática benigna
NO20004142D0 (no)	2000-08-18	Ftalimidoarylpiperaziner som <alfa> 1A reseptorantagonister anvendelige ved behandling av benign prostatahyperplasi
EP1435913A4 (en)	2007-10-24	METHOD OF TREATING BENIGN PROSTATIC HYPERPLASIA AND OTHER BENCH PROSTATIC PATHOLOGIES
GB9810895D0 (en)	1998-07-22	Combination therapy for the treatment of benign prostatic hyperplasia
AU2003204320A1 (en)	2003-06-19	Heterocycles useful in the treatment of benign prostatic hyperplasia and intermediates thereof
ECSP982362A (es)	1998-12-22	Compuestos de quinolina y quinazolina utiles en terapia
AU4118900A (en)	2000-12-28	Methods for the gene therapy of benign prostatic hyperplasia and medical agents therefore
GB9602903D0 (en)	1996-04-10	Conjugates useful in the treatment of benign prostatic hyperplasia
UA25095A (uk)	1998-12-25	Ліhімеhт для лікуваhhя каhдидозhого і змішаhого вульвовагіhіту
DK1056720T3 (da)	2005-02-21	Phtalimido-arylpiperaziner som alfa-1A-receptorantagonister, der er nyttige til behandling af godartet prostatahyperplasi
SI1501517T1 (sl)	2007-10-31	Farmacevtska kombinacija za zdravljenje benigne hiperplazije prostate ali za dolgotrajno preprečevanje akutne retencije urina